Expression and Clinical Significance of STAT3, P-STAT3, and VEGF-C in Small Cell Lung Cancer

Zhao, Xue; Sun, Xiaoqing; Li, Xiaoli

doi:10.7314/apjcp.2012.13.6.2873

Cited by 46 publications

(46 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, a compound with the ability to block the metastasis-associated steps could be a potential candidate for cancer chemoprevention and chemotherapy. It has been reported that the activation of STAT3 modulates the transcription of a variety of genes involved in the regulation of metastasis process, including ICAM-1 (Senggunprai et al, 2013) and vascular endothelium growth factor (Zhao et al, 2012). In this study, it was found that IL-6 increased the motility of CCA cells, and the specific JAK inhibitor, AG490, significantly decreased IL-6-dependent cell migration.…”

Section: Discussionmentioning

confidence: 50%

Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells

Aneknan

Kukongviriyapan²,

Prawan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 50%

Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells

Aneknan

Kukongviriyapan²,

Prawan³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Drug resistance is one of the most important reason for failure of SCLC treatment (Chen et al, 2012). Therefore, understanding of the molecular and biological mechanisms of SCLC would contribute to the development of new treatments (Zhao et al, 2012). Improved long-term survival has been observed through combined modality therapy in LS-SCLC (Turrisi et al, 1999).…”

Section: Discussionmentioning

confidence: 99%

“…Zhao et al (2012) studied about the expression levels of STAT3, P-STAT3, and VEGF-C in SCLC, and they found that the level of these markers higher than in normal tissue (p<0.05). They also showed positive correlations with clinical stage, tumor size, and lymph node metastasis (p<0.05).…”

Section: Discussionmentioning

confidence: 99%

“…They also showed positive correlations with clinical stage, tumor size, and lymph node metastasis (p<0.05). STAT3 and VEGF-C play important roles in the development of SCLC, and might be expected to become new targets for SCLC treatment (Zhao et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…SCLC exhibits aggressive behavior, with rapid growth, early distant metastasis. Although SCLC has a relatively good response to CT as well as TRT, relapse and progression may occur quickly, and the 5-year survival is 2% to 10% (Chao et al, 2012;Chen at al., 2012;Zhao et al, 2012). Drug resistance is one of the most important reason for failure of SCLC treatment (Chen et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution in Turkey

Bayman¹,

Etiz²,

Akçay³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: It is standard treatment to combine chemotherapy (CT) and thoracic radiotherapy (TRT) in treating patients with limited stage small cell lung cancer (LS-SCLC). However, optimal timing of TRT is unclear. We here evaluated the survival impact of early versus late TRT in patients with LS-SCLC. Materials and Methods: Follow-up was retrospectively analyzed for seventy consecutive LS-SCLC patients who had successfully completed chemo-TRT between January 2006 and January 2012. Patients received TRT after either 1 to 2 cycles of CT (early TRT) or after 3 to 6 cycles of CT (late TRT). Survival and response rates were evaluated using the Kaplan-Meier method and comparisons were made using the multivariate Cox regression test. Results: Median follow-up was 24 (5 to 57) months. Carboplatin+etoposide was the most frequent induction CT (59%). Median overall, disease free, and metastasis free survivals in all patients were 15 (5 to 57), 5 (0 to 48) and 11 (3 to 57) months respectively. Late TRT was superior to early TRT group in terms of response rate (p=0.05). 3 year overall survival (OS) rates in late versus early TRT groups were 31% versus 17%, respectively (p=0.03). Early TRT (p=0.03), and incomplete response to TRT (p=0.004) were negative predictors of OS. Significant positive prognostic factors for distant metastasis free survival were late TRT (p=0.03), and use of PCI (p=0.01). Use of carboplatin versus cisplatin for induction CT had no significant impact on OS (p=0.634), DFS (p=0.727), and MFS (p=0.309). Conclusions: Late TRT appeared to be superior to early TRT in LS-SCLC treatment in terms of complete response, OS and DMFS. Carboplatin or cisplatin can be combined with etoposide in the induction CT owing to similar survival outcomes.

show abstract

Retracted: Correlation of the expressions of IGF1R‐RACK1‐STAT3 and Bcl‐xl in nasopharyngeal carcinoma with the clinicopathological features and prognosis of nasopharyngeal carcinoma

Wang

Shen

Wen

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

The aim of this study was to investigate the correlation of expression of IGF1R-RACK1-STAT3 and Bcl-xl in nasopharyngeal carcinoma (NPC) with the clinicopathological features and the prognosis of NPC. Our study selected 215 NPC tissues and 178 chronic nasopharyngitis tissues (control group). Positive expression rates of IGF1R, RACK1, STAT3, and Bcl-xl were tested by immunohistochemical method, and expression of IGF1R, RACK1, STAT3, Bcl-xl, Bcl-2, and Bax by western blotting. Correlation of IGF1R, RACK1, STAT3, and Bcl-xl with the clinicopathological features of NPC was analyzed. The correlation among those four expression was analyzed by Spearman. The survival of NPC and independent factors of prognosis were tested by Kaplan-Meier and COX proportional hazards model respectively. The NPC group had higher positive expression rates of IGF1R, RACK1, STAT3, and Bcl-xl, and elevated expression of IGF1R, RACK1, STAT3, Bcl-xl, Bcl-2, and Bax. The lymph node metastasis (LNM) group had higher positive expression rates of IGF1R and RACK1 when compared with the non-LNM group. Patients with stage III and IV had higher positive expression rates of IGF1R, RACK1, STAT3, and Bcl-xl. There was positive correlation between expression of IGF1R and RACK1, STAT3. Such correlation was found between RACK1 and STAT3. Patients with negative expression of IGF1R, RACK1, STAT3, and Bcl-xl had higher survival rates. The risky factors of poor prognosis of NPC were positive expression of IGF1R, RACK1, STAT3 and Bcl-xl, and LNM. IGF1R-RACK1-STAT3 and Bcl-xl expression correlated with the clinicopathological features and poor prognosis of NPC.

show abstract

Expression and Clinical Significance of STAT3, P-STAT3, and VEGF-C in Small Cell Lung Cancer

Cited by 46 publications

References 15 publications

Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells

Luteolin Arrests Cell Cycling, Induces Apoptosis and Inhibits the JAK/STAT3 Pathway in Human Cholangiocarcinoma Cells

Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution in Turkey

Retracted: Correlation of the expressions of IGF1R‐RACK1‐STAT3 and Bcl‐xl in nasopharyngeal carcinoma with the clinicopathological features and prognosis of nasopharyngeal carcinoma

Contact Info

Product

Resources

About